Alterity Therapeutics Limited
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders, particularly Multiple System Atrophy (MSA) and related Parkinsonian diseases. The company is based in Melbourne, Australia with an additional presence in San Francisco, USA, and advances its programs through clinical development and a drug-discovery platform.
Liiketoiminta
Osuus liikevaihdostaATH434 and related clinical-stage development activities in MSA.
Earlier-stage programs targeting neurodegenerative disease biology.
Discovery work generating patentable compounds for neurological diseases.
Asiakkaat
Alterity does not sell commercial products to end consumers; its primary stakeholders are clinical investigators, trial sites, regulators, and future prescribing neurologists who would use approved therapies. In the current stage, the 'customer' is effectively the medical community and clinical-trial ecosystem that supports development and validation of its drug candidates.
They enroll patients and execute MSA and Parkinsonian-disorder trials to generate efficacy and safety data.
They are the eventual prescribers of any approved neurodegenerative-disease therapy.
They review trial design, safety, and quality data before and during development.
They participate in clinical studies and represent the unmet need the pipeline is designed to address.
Strategia
Alterity's core strategy is to advance ATH434 through late-stage clinical development in MSA, a rare disease with significant unmet need. It also maintains a discovery platform to extend its pipeline into related neurological diseases and create follow-on assets beyond the lead program.
The lead asset is the main value driver and the clearest path to clinical validation.
A broader label opportunity can expand the addressable market and support platform value.
Pipeline depth reduces dependence on a single asset and creates future partnering options.
Maantiede
Alterity is headquartered in Melbourne, Australia and also operates from San Francisco, USA. Its clinical and investor activity spans Australia and the United States, reflecting a cross-border biotech structure with U.S. capital markets access through NASDAQ and ASX listing presence.
Riskit
The company faces the typical clinical-stage biotech risks of trial failure, safety signals, regulatory delay, and uncertain translation from Phase 2 results into pivotal outcomes. Because Alterity depends heavily on a small number of neurological programs, execution risk around ATH434 and financing for development remain central.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
Therapeutic candidates may not reproduce Phase 2 efficacy or may fail pivotal endpoints.
Kohdistuu: ATH434 and MSA program
- Regulatory and trial execution delaysVaikutus: KorkeaTodennäköisyys: Korkea
Rare-disease studies depend on site activation, enrollment, and regulator alignment.
Kohdistuu: Phase 3 preparation and ongoing clinical operations
- Financing dilutionVaikutus: KorkeaTodennäköisyys: Korkea
Clinical-stage biotechnology typically requires repeated capital raising before commercialization.
Kohdistuu: Corporate funding and pipeline development
- Pipeline concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A limited number of programs increases the impact of any setback in the lead asset.
Kohdistuu: ATH434 and related neurodegeneration pipeline
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical work is expensed as incurred and is the main cost category.
Vaikutus: Affects operating loss and cash burn
Biotech companies often use equity awards to retain staff and conserve cash.
Vaikutus: Raises non-cash operating expenses and weakens comparability
Funding development commonly relies on share issues and option exercises.
Vaikutus: Changes share count and per-share valuation metrics
Investor assessment depends on available cash versus planned clinical spending.
Vaikutus: Influences liquidity interpretation and financing risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Allarity Therapeutics, Inc.
ALLR · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Pasithea Therapeutics Corp.
KTTA · Pharmaceutical Preparations
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Satellos Bioscience Inc.
MSLE · Pharmaceutical Preparations
Belite Bio, Inc
BLTE · Pharmaceutical Preparations
Belite Bio, Inc is a U.S.-based clinical-stage pharmaceutical company focused on developing oral therapies for degenerative retinal diseases with significant unmet medical need.
Päivitetty: 28.9.2026